- Home
- MDXH vs CHRS Comparison
MDXH vs CHRS Comparison
Compare MDXH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- CHRS
- Stock Information
- Founded
- MDXH 2003
- CHRS 2010
- Country
- MDXH Belgium
- CHRS United States
- Employees
- MDXH N/A
- CHRS N/A
- Industry
- MDXH
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDXH
- CHRS Health Care
- Exchange
- MDXH Nasdaq
- CHRS Nasdaq
- Market Cap
- MDXH 84.6M
- CHRS 84.2M
- IPO Year
- MDXH 2021
- CHRS 2014
- Fundamental
- Price
- MDXH $2.18
- CHRS $0.90
- Analyst Decision
- MDXH Buy
- CHRS Buy
- Analyst Count
- MDXH 1
- CHRS 3
- Target Price
- MDXH $6.00
- CHRS $4.68
- AVG Volume (30 Days)
- MDXH 61.1K
- CHRS 1.2M
- Earning Date
- MDXH 08-20-2025
- CHRS 08-07-2025
- Dividend Yield
- MDXH N/A
- CHRS N/A
- EPS Growth
- MDXH N/A
- CHRS N/A
- EPS
- MDXH N/A
- CHRS N/A
- Revenue
- MDXH $94,507,000.00
- CHRS $272,251,000.00
- Revenue This Year
- MDXH $23.51
- CHRS N/A
- Revenue Next Year
- MDXH $17.68
- CHRS $106.56
- P/E Ratio
- MDXH N/A
- CHRS N/A
- Revenue Growth
- MDXH 25.46
- CHRS 19.87
- 52 Week Low
- MDXH $1.35
- CHRS $0.66
- 52 Week High
- MDXH $3.50
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- MDXH 52.06
- CHRS 59.04
- Support Level
- MDXH $2.09
- CHRS $0.73
- Resistance Level
- MDXH $2.22
- CHRS $0.82
- Average True Range (ATR)
- MDXH 0.10
- CHRS 0.04
- MACD
- MDXH -0.01
- CHRS 0.02
- Stochastic Oscillator
- MDXH 59.52
- CHRS 88.02
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.